Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine

Drug Alcohol Rev. 2024 May;43(4):1013-1018. doi: 10.1111/dar.13826. Epub 2024 Feb 26.

Abstract

Introduction: This case series records a cohort of patients treated with transdermal buprenorphine patches as part of a buprenorphine microdose induction protocol to transition from methadone to buprenorphine in a community setting. This has historically been a difficult process to manage in community settings and this case series explored a method to gradually manage this in an outpatient setting.

Method: A retrospective file audit was conducted of the electronic medical records of cohealth Innerspace patients who had undergone buprenorphine microdose induction using transdermal patches. A total of 32 patients were identified.

Results: In this case series 23 of the 32 patients successfully transitioned from methadone to sublingual or long-acting injectable depot buprenorphine preparations utilising the transdermal buprenorphine microdosing technique. All patients in this case series regardless of the success of the transition were retained in treatment.

Discussion and conclusions: A fixed-dose transdermal buprenorphine patch regimen enabled 23 of 32 patients in this case series transition from methadone to buprenorphine in an outpatient setting. Given the small sample size further research is required to demonstrate the effectiveness of this technique.

Keywords: buprenorphine; microdosing; opioid substitution therapy; opioid use disorder.

Publication types

  • Case Reports

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Analgesics, Opioid / administration & dosage
  • Buprenorphine* / administration & dosage
  • Female
  • Humans
  • Male
  • Methadone* / administration & dosage
  • Middle Aged
  • Opiate Substitution Treatment* / methods
  • Opioid-Related Disorders / drug therapy
  • Retrospective Studies
  • Transdermal Patch*

Substances

  • Buprenorphine
  • Methadone
  • Analgesics, Opioid